More than 80% of patients with lung cancer receive care in their communities, but this can leave them vulnerable to gaps in care quality and delivery. Amivantamab's role in non–small cell lung ...

The study characterizes the lung cancer tumor microenvironment, linking cellular compositions to immunotherapy resistance and ...

The highly anticipated PROSPECT-Lung trial has officially opened, marking a significant step forward in the quest to improve treatment strategies for patients with resectable non-small cell lung ...

An FDA-approved drug used to treat multiple myeloma and lymphoma also shrank tumors in non-small cell lung cancer (NSCLC) ...

BioNTech resumes its PRESERVE-003 trial for gotistobart as a monotherapy in metastatic squamous NSCLC after a partial ...

Cibisatamab is a monoclonal antibody commercialized by Roche, with a leading Phase II program in Squamous Non-Small Cell Lung Cancer.

Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks BioNTech SE ( (BNTX) ) has provided an update.

Bizengri (zenocutuzumab-zbco) as the first and only treatment indicated for adults with pancreatic adenocarcinoma or ...

Incyte (NASDAQ:INCY) reported positive results from a Phase 3 study of its drug Zynyz in the treatment of non-small cell lung cancer ... previously untreated non-squamous and squamous metastatic ...

Duality Biologics revealed the first data from a global Phase 1/2a trial of BNT324/DB-1311, which it co-developed with ...

BioNTech (BNTX) said it has been informed by its partner OncoC4 that the Food and Drug Administration has lifted the partial clinical hold on ...

Rilvegostomig is a monoclonal antibody commercialized by AstraZeneca, with a leading Phase III program in Non-Small Cell Lung Cancer.